Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Interaction of BRCA1 and AR genes in breast cancer risk

Author: Alison Dunning

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Germline mutations in BRCA1 confer Mendelian inheritance of breast cancer in carrier families, but there remain large differences in age-at-onset of the cancer, which might be explained by modifier genes. Genes in the steroid hormone pathways are strong candidates for being such modifiers. Among these, androgen receptor (AR) gene expression is known to affect breast tumor growth and progression. The AR gene has an expressed CAG repeat polymorphism which alters the length of a glutamine tract in the protein and is inversely related to the transactivation efficiency of the AR signalling system. …
Literature
1.
Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am J Hum Genet. 1999, 64: 1371-1377.CrossRefPubMedPubMedCentral
Metadata
Title
Interaction of BRCA1 and AR genes in breast cancer risk
Author
Alison Dunning
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66583

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Paper Report

Raloxifene and breast cancer risk

Paper Report

BRCA1-associated DNA repair

Paper Report

Risk of breast cancer in women with palpable breast cysts

Research article

The Million Women Study: design and characteristics of the study population

Paper Report

Pathologic findings from the NSABP B-17 protocol: 8 year update

Paper Report

LOH in a transgenic model of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits